The estimated Net Worth of Eric Crombez is at least 2.82 百万$ dollars as of 2 May 2024. Eric Crombez owns over 354 units of Ultragenyx Pharmaceutical stock worth over 2,728,118$ and over the last 9 years Eric sold RARE stock worth over 88,273$.
Eric has made over 3 trades of the Ultragenyx Pharmaceutical stock since 2024, according to the Form 4 filled with the SEC. Most recently Eric sold 354 units of RARE stock worth 15,456$ on 2 May 2024.
The largest trade Eric's ever made was selling 1,238 units of Ultragenyx Pharmaceutical stock on 1 March 2024 worth over 66,555$. On average, Eric trades about 158 units every 6 days since 2016. As of 2 May 2024 Eric still owns at least 48,431 units of Ultragenyx Pharmaceutical stock.
You can see the complete history of Eric Crombez stock trades at the bottom of the page.
Eric's mailing address filed with the SEC is 840 Memorial Dr, Cambridge, MA 02139, USA.
Over the last 11 years, insiders at Ultragenyx Pharmaceutical have traded over 102,813,606$ worth of Ultragenyx Pharmaceutical stock and bought 203,500 units worth 4,623,050$ . The most active insiders traders include Group Holdings (Sbs) Adviso...、Llc Fmr、Clay B Siegall. On average, Ultragenyx Pharmaceutical executives and independent directors trade stock every 17 days with the average trade being worth of 573,045$. The most recent stock trade was executed by Emil D Kakkis on 3 September 2024, trading 20,000 units of RARE stock currently worth 1,117,000$.
ultragenyx is a clinical-stage biotechnology company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. our company is led by an experienced management team in rare disease therapeutics. recognizing that our primary responsibility is to our patients, we are working with advocacy groups to provide support and outreach to individuals and families affected by these disorders and engage them in the clinical testing process. we are also working with regulatory agencies to design and conduct high quality clinical studies that meet the requirements for approval. we are creating an improved model for successful rare disease d
Ultragenyx Pharmaceutical executives and other stock owners filed with the SEC include: